MedTrace Pharma A/S Financials, key figures and credit report
Net sales 1 759.4 kDKK FY 2025 -24.6% vs 2024
EBIT margin -1 471.6 % FY 2025 -464.2 pp vs 2024
Net debt -22 966.7 kDKK FY 2025 +30.8% vs 2024
Quick ratio 2.0 FY 2025 -1 vs 2024
Income statement (kDKK)
2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Fiscal period length | 12 | 12 | 12 | 12 | 12 |
| Net sales | 1 529.10 | 2 192.84 | 2 645.34 | 2 334.36 | 1 759.37 |
| Other operating income | 831.19 | 173.86 | 230.35 | 107.40 | |
| Costs of manufacturing | -1 155.57 | - 269.58 | - 606.28 | -2 098.28 | -2 061.54 |
| Gross profit | 373.53 | 1 923.26 | 2 039.06 | 236.08 | - 302.17 |
| Costs of management | -12 721.21 | -15 944.00 | -5 016.13 | -5 933.03 | -7 257.77 |
| Costs of distribution | -1 319.84 | -5 328.70 | -5 687.41 | ||
| Other operating expenses | -11 638.41 | -29 876.32 | -11 637.40 | -17 925.82 | -18 330.63 |
| EBIT | -24 474.74 | -49 051.90 | -20 071.53 | -23 515.37 | -25 890.57 |
| Other financial income | 41.63 | 70.68 | 3 505.46 | 4 004.40 | 810.30 |
| Other financial expenses | - 445.15 | - 973.43 | -1 591.23 | -1 294.96 | - 851.99 |
| Pre-tax profit | -24 878.26 | -49 969.57 | -18 157.30 | -20 805.93 | -25 932.26 |
| Income taxes | 7 026.57 | 12 919.17 | 3 050.80 | 5 450.05 | -9 198.85 |
| Net earnings | -17 851.68 | -37 050.40 | -15 106.50 | -15 355.88 | -35 131.11 |
Assets (kDKK)
2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Intangible rights | 62 658.32 | 79 400.13 | 149 702.73 | 222 612.52 | 284 254.22 |
| Intangible assets total | 62 658.32 | 79 400.13 | 149 702.73 | 222 612.52 | 284 254.22 |
| Machinery and equipment | 6 512.56 | 7 888.84 | 7 342.05 | 10 236.59 | 8 912.25 |
| Other tangible assets | 2 002.24 | 11 700.80 | 9 658.96 | 7 139.80 | 4 765.44 |
| Tangible assets total | 8 514.81 | 19 589.64 | 17 001.01 | 17 376.39 | 13 677.69 |
| Other non-current investments | 767.57 | -1 473.03 | 1 331.10 | 1 517.14 | 1 536.01 |
| Investments total | 767.57 | -1 473.03 | 1 331.10 | 1 517.14 | 1 536.01 |
| Deferred tax assets | 2 426.86 | ||||
| Long term receivables total | 2 426.86 | ||||
| Inventories total | 404.08 | 4 307.23 | 5 996.82 | 2 462.30 | 1 434.94 |
| Current trade debtors | 13 771.32 | 544.56 | |||
| Current other receivables | 3 337.89 | 11 487.63 | 5 746.17 | -7 962.30 | 6 583.21 |
| Current deferred tax assets | 5 500.00 | 5 500.00 | 5 500.00 | 5 500.00 | 5 500.00 |
| Short term receivables total | 8 837.89 | 16 987.63 | 11 246.17 | 11 309.02 | 12 627.77 |
| Cash and bank deposits | 38 333.34 | 69 446.26 | 122 317.41 | 34 317.32 | 23 564.26 |
| Cash and cash equivalents | 38 333.34 | 69 446.26 | 122 317.41 | 34 317.32 | 23 564.26 |
| Balance sheet total (assets) | 119 516.00 | 190 684.72 | 307 595.24 | 289 594.69 | 337 094.89 |
Equity and liabilities (kDKK)
2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Share capital | 2 010.49 | 2 716.08 | 4 996.83 | 5 000.66 | 11 178.91 |
| Other reserves | -70.49 | -85.41 | -90.50 | -66.48 | - 203.70 |
| Retained earnings | 109 618.22 | 195 610.31 | 295 437.49 | 280 486.43 | 326 769.54 |
| Profit of the financial year | -17 851.68 | -37 050.40 | -15 106.50 | -15 355.88 | -35 131.11 |
| Shareholders equity total | 93 706.53 | 161 190.57 | 285 237.32 | 270 064.73 | 302 613.64 |
| Non-current loans from credit institutions | 5 484.20 | 3 749.57 | 1 006.49 | 525.65 | |
| Non-current leasing loans | 68.50 | 6 119.34 | 6 119.34 | 3 869.53 | 2 256.91 |
| Non-current deferred tax liabilities | 5 069.35 | 14 301.01 | |||
| Non-current liabilities total | 10 622.05 | 9 868.91 | 7 125.83 | 4 395.18 | 16 557.91 |
| Current loans from credit institutions | 152.32 | 609.28 | 609.28 | 597.59 | |
| Current leasing loans | 210.19 | 1 884.78 | 1 164.09 | 2 074.19 | 2 110.27 |
| Current trade creditors | 9 141.60 | 3 267.13 | 6 278.84 | 4 795.44 | 6 035.36 |
| Other non-interest bearing current liabilities | 546.47 | 12 171.57 | 5 415.78 | 6 472.39 | 9 081.44 |
| Accruals and deferred income | 5 289.15 | 2 149.44 | 1 764.11 | 1 183.48 | 98.67 |
| Current liabilities total | 15 187.41 | 19 625.24 | 15 232.09 | 15 134.78 | 17 923.33 |
| Balance sheet total (liabilities) | 119 516.00 | 190 684.72 | 307 595.24 | 289 594.69 | 337 094.89 |
Secure checkout
Buy AI Credit Risk Report
Pay by card and the report is generated automatically and sent to your email. One-time payment – no subscription.
How it works
- 01 You pay €3 (incl. VAT) securely by card via Stripe.
- 02 You enter your email address in Stripe's payment window – the report is sent there.
- 03 The report is generated automatically and sent as a PDF within 30 minutes.
- 04 If generation should fail, you are not charged.
- 05 You receive the receipt by email once the report has been generated and completed.
Do you want to buy the AI Credit Risk Report (3 EUR / report)?
The report is sent to the email address you enter in Stripe's payment window. Please also check your spam folder. Questions? Write to info@creditreports.dk.
Page generated